.png){kind=icon}
.png){kind=icon}
Return
Translating genomic data into healthcare practice with the Singapore National Precision Medicine program
.png){kind=icon}
PRE
AI
S
T
M
N
C
B
P
P
X
P
T
S
H
J
K
A
K
D
王
M
J
E
C
J
W
E
K
D
I
Y
W
S
R
M
T
W
M
J
S
K
C
C
X
B
C
N
E
M
E
J
P
DOI：10.1038/s41588-026-02687-8.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The Singapore National Precision Medicine (NPM) program is a three-phase whole-of-nation effort designed to develop scalable, evidence-based solutions for precision health tailored to Asia’s diverse populations. Here we present NPM phase II (2020–2025), highlighting how large-scale precision medicine initiatives can drive new research insights, enable healthcare innovations and create economic value. Key achievements include the PRECISE-SG100K population dataset, which reflects Singapore’s unique multi-ancestry Asian population; the successful translation of research findings into mainstream national healthcare using familial hypercholesterolemia as a use case; and the establishment of strategic public–private partnerships with diverse industry sectors. We also outline phase III (2025–2031), which aims to establish whole-genome sequencing as a foundational element of a patient’s lifelong healthcare record for 10% of the population. NPM provides a model for how smaller countries, despite limited populations and finite resources, can contribute meaningfully to global scientific movements while preserving strategic independence and addressing national health challenges. Singapore’s National Precision Medicine program phase II establishes a multi-ancestry Asian population cohort, national-scale genetic testing and public–private partnerships, demonstrating how small countries can contribute to global genomics efforts.
Journal
IF:
29
Papers:
689
Citations:
241
Organization
Cited Papers